CN110568114B - Solid phase microextraction-high performance liquid chromatography on-line combined detection method for zoledronic acid and risedronic acid - Google Patents
Solid phase microextraction-high performance liquid chromatography on-line combined detection method for zoledronic acid and risedronic acid Download PDFInfo
- Publication number
- CN110568114B CN110568114B CN201910805620.5A CN201910805620A CN110568114B CN 110568114 B CN110568114 B CN 110568114B CN 201910805620 A CN201910805620 A CN 201910805620A CN 110568114 B CN110568114 B CN 110568114B
- Authority
- CN
- China
- Prior art keywords
- monolithic column
- column
- solution
- acid
- liquid chromatography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 229960000759 risedronic acid Drugs 0.000 title claims abstract description 35
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 229960004276 zoledronic acid Drugs 0.000 title claims abstract description 35
- 238000001514 detection method Methods 0.000 title claims abstract description 31
- 238000004128 high performance liquid chromatography Methods 0.000 title claims abstract description 21
- 239000007790 solid phase Substances 0.000 title claims abstract description 21
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 44
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 44
- 230000033558 biomineral tissue development Effects 0.000 claims abstract description 32
- 238000011065 in-situ storage Methods 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 32
- 238000004458 analytical method Methods 0.000 claims abstract description 18
- 239000011159 matrix material Substances 0.000 claims abstract description 17
- 238000002470 solid-phase micro-extraction Methods 0.000 claims abstract description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 72
- 239000000243 solution Substances 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 21
- 239000000523 sample Substances 0.000 claims description 21
- 229910001868 water Inorganic materials 0.000 claims description 19
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 18
- 238000011068 loading method Methods 0.000 claims description 18
- 238000001802 infusion Methods 0.000 claims description 16
- 239000003480 eluent Substances 0.000 claims description 14
- 239000012071 phase Substances 0.000 claims description 14
- 239000004696 Poly ether ether ketone Substances 0.000 claims description 13
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 claims description 13
- 229920002530 polyetherether ketone Polymers 0.000 claims description 13
- 229920001807 Urea-formaldehyde Polymers 0.000 claims description 12
- 239000008055 phosphate buffer solution Substances 0.000 claims description 11
- -1 polytetrafluoroethylene Polymers 0.000 claims description 10
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 10
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 10
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 claims description 9
- 229960003638 dopamine Drugs 0.000 claims description 9
- 238000011049 filling Methods 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 229920001690 polydopamine Polymers 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- 239000012488 sample solution Substances 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 3
- 239000007832 Na2SO4 Substances 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 238000013375 chromatographic separation Methods 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000008098 formaldehyde solution Substances 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 239000012890 simulated body fluid Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000011010 flushing procedure Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 15
- 239000012535 impurity Substances 0.000 abstract description 6
- 230000009881 electrostatic interaction Effects 0.000 abstract description 3
- 238000004811 liquid chromatography Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 208000001132 Osteoporosis Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000003993 interaction Effects 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 125000005340 bisphosphate group Chemical group 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/22—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the construction of the column
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N30/08—Preparation using an enricher
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N2030/062—Preparation extracting sample from raw material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
The invention discloses a solid phase microextraction-high performance liquid chromatography online combined detection method for zoledronic acid and risedronic acid. The invention firstly prepares a hydroxyapatite functionalized monolithic column by an in-situ mineralization method, then uses the monolithic column as a solid phase micro-extraction monolithic column, and combines a solid phase micro-extraction-high performance liquid chromatography online combined system to establish a solid phase micro-extraction-high performance liquid chromatography online combined detection method for zoledronic acid and risedronic acid. The invention realizes the high-efficiency extraction and enrichment of zoledronic acid and risedronic acid by utilizing the specific electrostatic interaction between hydroxyapatite on the surface of the monolithic column and a P-C-P structure carried by an analysis object, and eliminates the interference of impurities in a sample matrix on analysis and detection. The method is simple, the process is ingenious, the required instruments are high in popularity and easy to popularize, the efficient extraction and enrichment of trace zoledronic acid and risedronic acid in a complex actual sample can be realized, and the related high-sensitivity detection requirements are met.
Description
Technical Field
The invention belongs to the field of analytical chemistry, and particularly relates to a solid-phase microextraction-high performance liquid chromatography online combined detection method for zoledronic acid and risedronic acid.
Background
Osteoporosis, is a metabolic bone disorder characterized by a reduction in the amount of bone tissue per unit volume. At present, osteoporosis is promoted to the seventh common disease and frequently-occurring disease in China, the incidence rate is increased year by year, and the condition is not optimistic. According to statistics, the current 8800 ten thousand people in China suffer from osteoporosis, and the total disease rate is 12.4%; among them, the prevalence rate of the elderly over 65 years old is over 50%, and the incidence rate of fracture is nearly one third. Drugs clinically used for treating osteoporosis are mainly classified into basic supplements, bone resorption-inhibiting drugs and bone formation-promoting drugs according to the occurrence of diseases. Bisphosphates represented by zoledronic acid and risedronic acid are widely used clinically as bone resorption inhibiting agents because of their good therapeutic effects. However, administration of bisphosphonates also causes side effects such as vomiting, diarrhea, dizziness, and if it is taken excessively for a long period of time, diseases such as deterioration of renal function may occur. Therefore, the content detection of the medicines in the human body is very important for ensuring the treatment effect of the osteoporosis and ensuring the medication safety.
Hydroxyapatite (HAP) is the main mineral component of natural bone tissue and teeth, is a crystalline form of calcium phosphate, and has a structural formula of Ca10(PO4)6(OH)2Consisting of a positively charged pair of crystalline calcium ions (C site) and six negatively charged clusters of oxygen atoms (P site). HAP, as a biological separation and purification material, dates back to 1956 for the first time, and the action mechanism thereof comprises anion exchange at C site, cation exchange at P site and coordination of calcium ion. Because the chemical structures of the diphosphonate substances such as zoledronic acid, risedronic acid and the like are provided with structures in which two phosphate groups are connected with one carbon atom (P-C-P), the substances can generate strong specific anion exchange interaction with calcium ion pairs (namely C sites) on HAP, which is not only the pharmacodynamic action mechanism of the medicaments, but also provides a new idea for developing selective extraction and enrichment materials of the medicaments. Firstly, preparing a hydroxyapatite functionalized monolithic column by an in-situ mineralization method; then the monolithic column is used as a solid phase micro-extraction monolithic column, the specific electrostatic interaction between the HAP on the surface of the monolithic column and the P-C-P structures carried by the zoledronic acid and the risedronic acid is utilized to realize the high-efficiency extraction and enrichment of the zoledronic acid and the risedronic acid, and the interference of impurities in a sample matrix on analysis and detection is eliminated; and an online combined detection method of the zoledronic acid and the risedronic acid is established by combining a solid phase microextraction-high performance liquid chromatography online combined system. At present, no relevant report of on-line enrichment extraction of zoledronic acid and risedronic acid by using HAP functionalized monolithic column exists.
Disclosure of Invention
The invention aims to provide a solid phase microextraction-high performance liquid chromatography online combined detection method for zoledronic acid and risedronic acid. Firstly, preparing a hydroxyapatite functionalized monolithic column by an in-situ mineralization method; then the monolithic column is used as a solid phase micro-extraction monolithic column; the specific electrostatic interaction between the C site on the HAP particles generated by in-situ mineralization on the surface of the monolithic column and the P-C-P structure is benefited to realize the efficient extraction, enrichment and online purification of trace zoledronic acid and risedronic acid in a complex biological sample; and then, establishing an online combined detection method for the zoledronic acid and the risedronic acid by combining a solid phase microextraction-high performance liquid chromatography online combined system.
In order to achieve the purpose, the invention adopts the following technical scheme:
1) the hydroxyapatite functionalized monolithic column prepared by the in-situ mineralization method comprises the following steps:
first step, preparing a matrix monolithic column: cleaning a polytetrafluoroethylene empty tube with chromatographic pure methanol for half an hour, and then placing the polytetrafluoroethylene empty tube in a 60 ℃ oven for drying; 1g/mL urea aqueous solution, 37% formaldehyde solution and 0.1mol/L hydrochloric acid solution are mixed according to the weight ratio of 4: 5: 1, putting the mixture into a polytetrafluoroethylene tube which is cleaned in advance, and reacting in a water bath at the temperature of between 45 and 65 ℃ for 10 to 120 minutes to prepare a urea-formaldehyde resin matrix monolithic column;
and secondly, coating polydopamine: washing the urea resin matrix monolithic column with water for 1 hour by a micro-infusion pump, and removing unreacted substances in the column; meanwhile, 5mL of 10mmol/L Tris-HCl solution with the pH value of 8.0 is taken, 10mg of dopamine is added, and the solution is dissolved, uniformly mixed and then kept stand for 5 minutes to prepare dopamine solution; then, a trace infusion pump is used for filling the urea-formaldehyde resin matrix monolithic column with the dopamine solution; then, standing for 3 hours without closing the two ends of the monolithic column; continuously repeating the operation twice to obtain a urea-formaldehyde resin integral column coated with the polydopamine on the surface;
thirdly, in-situ mineralization generation of hydroxyapatite: firstly, 354.5mg of NaCl and 15.9mg of NaHCO were weighed3、16.8mg KCl、16.1mg Na2HPO4、6.4mg MgCl2、12.5mg CaCl2、3.2mg Na2SO4Dissolving in 30mL of deionized water to prepare simulated body fluid; filling the monolithic column with the polydopamine coated surface by using a micro-infusion pump; sealing two ends of the monolithic column by using gaskets, and placing the monolithic column in a water bath at 37 ℃ for incubation for 3 days; then, the whole column is taken out, water is taken as a mobile phase, and a micro-infusion pump is used for flushingWashing for 1 hour; and continuously repeating the operation twice to obtain the hydroxyapatite functionalized monolithic column prepared by the in-situ mineralization method. The monolithic column is balanced with methanol for half an hour before use.
Wherein the polytetrafluoroethylene tube has a length of 10cm and an inner diameter of 750 μm.
2) The construction and operation of the solid phase micro-extraction-high performance liquid chromatography online combined system are as follows:
the on-line combined system of solid phase micro-extraction-high performance liquid chromatography comprises a ten-way valve, a six-way valve, a hydroxyapatite functionalized monolithic column prepared by an in-situ mineralization method, a liquid chromatography infusion pump-pump A, a 0.5mL PEEK tube quantitative ring, a liquid chromatography infusion pump-pump B, a 0.2mL PEEK tube quantitative ring, a liquid chromatography analysis column and a detector.
The combined system comprises the following specific operation steps:
firstly, a ten-way valve and a six-way valve are both in the LOAD position; the loading liquid passes through a hydroxyapatite functionalized monolithic column prepared by a pump A balance in-situ mineralization method, and the flow rate is 0.2 mL/min; the mobile phase passes through the analytical column directly by a pump B to obtain a stable baseline required by chromatographic separation, and the flow rate is 1.0 mL/min; meanwhile, filling a sample solution into a 0.5mL PEEK tube quantitative ring through a sample injection needle;
when the six-way valve is adjusted to the INJECT position, solid phase micro-extraction starts, a sample in a 0.5mL PEEK tube quantitative ring is brought into a hydroxyapatite functionalized monolithic column prepared by an in-situ mineralization method through loading liquid, and the six-way valve is adjusted back to the LOAD position after a given time;
thirdly, the solution conveyed by the pump A is changed into eluent from loading liquid, the flow rate is set to be 0.1mL/min, the eluent is utilized to elute the enriched analysis object on the hydroxyapatite functionalized monolithic column prepared by the in-situ mineralization method, and the enriched analysis object is collected in a 0.2mL PEEK tube quantitative ring; when the elution is completed, the ten-way valve is adjusted to the INJECT position, the collected eluent is sent to a liquid chromatographic column by using the mobile phase for separation, and then the detection is carried out by using a detector.
Wherein, the sample solution and the loading solution consist of: according to the volume fraction ratio, the methanol/water is 70/30; the mobile phase is as follows: methanol/15 mmol/L phosphate buffer solution (containing 5mmol/L tetrabutylammonium bromide) with pH 7.0 of 30/70; the eluent is phosphate buffer solution with the pH value of 7.0 of 15 mmol/L; the analytical column is a C18 liquid chromatographic analytical column; the detector is a diode array detector; the column oven temperature was 40 ℃ and the detection wavelengths were 220nm (zoledronic acid) and 260nm (risedronic acid).
The invention has the following remarkable advantages:
1) the HAP functionalized monolithic column prepared by the in-situ mineralization method is used as a solid-phase micro-extraction medium, the HAP coverage degree of the surface of the monolithic column is high, the action probability between zoledronic acid, risedronic acid and HAP can be improved, the specific interaction between the zoledronic acid and risedronic acid is enhanced, and the specific extraction capability of the monolithic column is improved; meanwhile, the influence of other impurities in the actual sample on the enrichment extraction of the analysis object can be reduced, and the high-efficiency enrichment extraction and high-sensitivity detection of the analysis object are realized.
2) The HAP functionalized monolithic column prepared by the in-situ mineralization method keeps the excellent permeability of the matrix monolithic column, so that higher flow rate can be used in the solid-phase microextraction operation, the operation efficiency of analysis and detection is improved, the cleaning and regeneration of the monolithic column are facilitated, the service life of the monolithic column is prolonged, and the stability and the reproducibility of the method are improved.
Drawings
FIG. 1 is a schematic structural diagram of a solid phase microextraction-high performance liquid chromatography on-line combined system.
FIG. 2 shows that when an HAP functionalized monolithic column prepared by an in-situ mineralization method is used as a solid-phase microextraction medium to construct a solid-phase microextraction-high performance liquid chromatography online combined system, and online enrichment detection is performed on zoledronic acid and risedronic acid, the influence of the methanol content in a loading liquid on the sample enrichment efficiency is realized.
FIG. 3 is a chromatogram of on-line enrichment detection of trace amounts of zoledronic acid and risedronic acid added to a blank serum sample by using an HAP functionalized monolithic column prepared by an in-situ mineralization method as a solid-phase microextraction medium to construct a solid-phase microextraction-high performance liquid chromatography on-line combined system. FIG. 3-a is an on-line system analysis chromatogram of a spiked serum sample; FIG. 3-b is a chromatogram of a conventional liquid chromatography system for measuring a spiked serum sample.
Detailed Description
In order to make the present invention more comprehensible, the technical solutions of the present invention are further described below with reference to specific embodiments, but the present invention is not limited thereto.
Step one, preparing a hydroxyapatite functionalized monolithic column by an in-situ mineralization method:
(1) preparing a matrix monolithic column: cleaning a polytetrafluoroethylene empty tube with chromatographic pure methanol for half an hour, and then placing the polytetrafluoroethylene empty tube in a 60 ℃ oven for drying; 1g/mL urea aqueous solution, 37% formaldehyde solution and 0.1mol/L hydrochloric acid solution are mixed according to the weight ratio of 4: 5: 1, putting the mixture into a polytetrafluoroethylene tube which is cleaned in advance, and reacting in a water bath at 55 ℃ for 10 minutes to obtain the urea-formaldehyde resin matrix monolithic column.
(2) Coating of polydopamine: washing the urea resin matrix monolithic column with water for 1 hour by a micro-infusion pump, and removing unreacted substances in the column; meanwhile, 5mL of 10mmol/L Tris-HCl solution with the pH value of 8.0 is taken, 10mg of dopamine is added, and the solution is dissolved, uniformly mixed and then kept stand for 5 minutes to prepare dopamine solution; then, a trace infusion pump is used for filling the urea-formaldehyde resin matrix monolithic column with the dopamine solution; then, standing for 3 hours without closing the two ends of the monolithic column; continuously repeating the operation twice to obtain a urea-formaldehyde resin integral column coated with the polydopamine on the surface;
(3) in-situ mineralization generation of hydroxyapatite: firstly, 354.5mg of NaCl and 15.9mg of NaHCO were weighed3、16.8mg KCl、16.1mg Na2HPO4、6.4mg MgCl2、12.5mg CaCl2、3.2mg Na2SO4Dissolving in 30mL of deionized water to prepare simulated body fluid; filling the monolithic column with the polydopamine coated surface by using a micro-infusion pump; sealing two ends of the monolithic column by using gaskets, and placing the monolithic column in a water bath at 37 ℃ for incubation for 3 days; then, taking out the monolithic column, taking water as a mobile phase, and flushing for 1 hour by using a micro-infusion pump; and continuously repeating the operation twice to obtain the hydroxyapatite functionalized monolithic column prepared by the in-situ mineralization method. The monolithic column is balanced with methanol for half an hour before use.
Step two, the construction and operation of a solid phase micro-extraction-high performance liquid chromatography online combined system:
the on-line combined system of solid phase micro-extraction-high performance liquid chromatography comprises a ten-way valve, a six-way valve, a hydroxyapatite functionalized monolithic column prepared by an in-situ mineralization method, a liquid chromatography infusion pump-pump A, a 0.5mL PEEK tube quantitative ring, a liquid chromatography infusion pump-pump B, a 0.2mL PEEK tube quantitative ring, a liquid chromatography analysis column and a detector.
The online combination system comprises the following specific operation steps:
firstly, a ten-way valve and a six-way valve are both in the LOAD position; the loading liquid passes through a hydroxyapatite functionalized monolithic column prepared by a pump A balance in-situ mineralization method, and the flow rate is 0.2 mL/min; the mobile phase passes through the analytical column directly by a pump B to obtain a stable baseline required by chromatographic separation, and the flow rate is 1.0 mL/min; meanwhile, filling a sample solution into a 0.5mL PEEK tube quantitative ring through a sample injection needle;
when the six-way valve is adjusted to the INJECT position, solid phase micro-extraction starts, a sample in a 0.5mL PEEK tube quantitative ring is brought into a hydroxyapatite functionalized monolithic column prepared by an in-situ mineralization method through loading liquid, and after 3.5 minutes, the six-way valve is adjusted back to the LOAD position;
thirdly, the solution conveyed by the pump A is changed into eluent from loading liquid, the flow rate is set to be 0.1mL/min, the eluent is utilized to elute the enriched analysis object on the hydroxyapatite functionalized monolithic column prepared by the in-situ mineralization method, and the enriched analysis object is collected in a 0.2mL PEEK tube quantitative ring; when the elution is completed, the ten-way valve is adjusted to the INJECT position, the collected eluent is sent to a liquid chromatographic column by using the mobile phase for separation, and then the detection is carried out by using a detector.
Wherein, the sample solution and the loading solution consist of: according to the volume fraction ratio, the methanol/water is 70/30; the mobile phase is as follows: methanol/15 mmol/L phosphate buffer solution (containing 5mmol/L tetrabutylammonium bromide) with pH 7.0 of 30/70; the eluent is phosphate buffer solution with the pH value of 7.0 of 15 mmol/L; the analytical column is a C18 liquid chromatographic analytical column; the detector is a diode array detector; the column oven temperature was 40 ℃ and the detection wavelengths were 220nm (zoledronic acid) and 260nm (risedronic acid).
Application example 1
Firstly, preparing an HAP functionalized monolithic column by an in-situ mineralization method according to the embodiment, and taking the monolithic column as a solid phase micro-extraction monolithic column; then, a solid phase microextraction-high performance liquid chromatography online combined analysis system is constructed according to the figure 1, and the influence of the methanol content in the loading liquid on the sample enrichment efficiency is examined when online enrichment detection is carried out on zoledronic acid (ZOD) and risedronic acid (RID). The loading liquid consists of methanol and H2O, the sample solution composition is methanol/H2O is 70/30(v/v), the injection flow rate is 0.2mL/min, and the injection volume is 500 muL; the eluent composition was 15mmol/L phosphate buffer solution with pH 7.0, elution flow rate 0.1mL/min, elution volume 200 μ L (collection from 0.5 min to 2.5 min); the mobile phase was separated from methanol/15 mmol/L phosphate buffer solution (containing 5mmol/L tetrabutylammonium bromide) at pH 7.0 30/70(v/v), the separation flow rate was 1mL/min, the column oven temperature was 40 ℃, and the detection wavelengths were 220nm (zoledronic acid) and 260nm (risedronic acid), respectively.
As shown in FIG. 2, the efficiency of zoledronic acid and risedronic acid extraction increases significantly as the methanol content of the carrier liquid increases. During the extractive enrichment of analytes, a key role is played by the specific anion exchange interaction between the P-C-P structure in the analyte and the C site on the HAP. This specific force is enhanced when the methanol content is increased, improving the extraction efficiency, since the water in the loading liquid can compete with the assay for the C sites on the HAP, impairing the interaction. However, when the methanol content is increased from 70% (v/v) to 80% (v/v), the extraction efficiency is rather decreased, because the solubility of the strongly polar substances zoledronic acid and risedronic acid in the solution is decreased due to the excessively high methanol content, resulting in the decrease of the extraction efficiency of zoledronic acid and risedronic acid. Therefore, we chose the loading liquid methanol ratio of 70% (v/v) as the optimum ratio.
Application example 2
Firstly preparing HAP functionalized monolithic column by in-situ mineralization method according to the embodiment, and using the monolithic columnAs solid phase micro extraction monolithic column; then, a solid phase microextraction-high performance liquid chromatography online combined analysis system is constructed according to the figure 1, and trace amounts of zoledronic acid and risedronic acid added in a blank serum sample are enriched and detected on line. The sample injection sample solution and the loading solution consist of methanol/H2O is 70/30(v/v), the injection flow rate is 0.2mL/min, and the injection volume is 500 muL; the eluent composition was 15mmol/L phosphate buffer solution with pH 7.0, elution flow rate 0.1mL/min, elution volume 200 μ L (collection from 0.5 min to 2.5 min); the mobile phase was separated from methanol/15 mmol/L phosphate buffer solution (containing 5mmol/L tetrabutylammonium bromide) at pH 7.0 30/70(v/v), the separation flow rate was 1mL/min, the column oven temperature was 40 ℃, and the detection wavelengths were 220nm (zoledronic acid) and 260nm (risedronic acid), respectively.
FIG. 3 is a chromatogram of the online enrichment detection system for trace amounts of zoledronic acid and risedronic acid added to a blank serum sample. In FIG. 3-a, peak 1 was zoledronic acid and peak 2 was risedronic acid. As can be seen from the figure 3-a, under the condition of the combined system, the HAP functionalized monolithic column prepared by the in-situ mineralization method eliminates the interference of a large amount of impurities such as protein, lipid, carbohydrate and the like in a serum sample matrix on analysis and detection, and realizes the high-efficiency enrichment extraction and high-sensitivity detection of trace amounts of zoledronic acid and risedronic acid added in a blank serum sample. When the same sample is analyzed using the direct sample injection mode of the conventional liquid chromatography system, the impurities in the serum sample matrix cause strong interference with the detection of the analyte and overlap with the absorption peak of the analyte (fig. 3-b). This shows that the HAP functionalized monolithic column prepared by the in-situ mineralization method has excellent impurity removal capability and strong specific extraction performance.
The above description is only a preferred embodiment of the present invention, and all equivalent changes and modifications made in accordance with the claims of the present invention should be covered by the present invention.
Claims (1)
1. The solid phase microextraction-high performance liquid chromatography on-line combined detection method of zoledronic acid and risedronic acid is characterized in that: the detection method is characterized in that a hydroxyapatite functionalized monolithic column prepared by an in-situ mineralization method is used as a solid-phase microextraction monolithic column, and a solid-phase microextraction-high performance liquid chromatography online combined detection method of zoledronic acid and risedronic acid is established by combining a solid-phase microextraction-high performance liquid chromatography online combined system; the method is used for detecting serum samples;
the preparation method of the hydroxyapatite functionalized monolithic column comprises the following steps:
(1) preparing a matrix monolithic column: cleaning a polytetrafluoroethylene empty tube with chromatographic pure methanol for half an hour, and then placing the polytetrafluoroethylene empty tube in a 60 ℃ oven for drying; 1g/mL urea aqueous solution, 37% formaldehyde solution and 0.1mol/L hydrochloric acid solution are mixed according to the weight ratio of 4: 5: 1, putting the mixture into a polytetrafluoroethylene tube which is cleaned in advance, and reacting in a water bath at 55 ℃ for 10 minutes to obtain a urea-formaldehyde resin matrix monolithic column;
(2) coating of polydopamine: washing the urea resin matrix monolithic column with water for 1 hour by a micro-infusion pump, and removing unreacted substances in the column; meanwhile, taking 5mL of 10mmol/L Tris-HCl solution with pH =8.0, adding 10mg of dopamine, dissolving and uniformly mixing, and standing for 5 minutes to prepare dopamine solution; then, a trace infusion pump is used for filling the urea-formaldehyde resin matrix monolithic column with the dopamine solution; then, standing for 3 hours without closing the two ends of the monolithic column; continuously repeating the operation twice to obtain a urea-formaldehyde resin integral column coated with the polydopamine on the surface;
(3) in-situ mineralization generation of hydroxyapatite: firstly, 354.5mg of NaCl and 15.9mg of NaHCO were weighed3、16.8 mg KCl、16.1 mg Na2HPO4、6.4 mg MgCl2、12.5 mg CaCl2、3.2 mg Na2SO4Dissolving in 30mL of deionized water to prepare simulated body fluid; filling the monolithic column with the polydopamine coated surface by using a micro-infusion pump; sealing both ends of the monolithic column by using gaskets, and placing the monolithic column in a water bath at 37 ℃ for incubation for 3 days; then, taking out the monolithic column, taking water as a mobile phase, and flushing for 1 hour by using a micro-infusion pump; continuously repeating the operation twice to obtain a hydroxyapatite functionalized monolithic column prepared by an in-situ mineralization method; before the monolithic column is used, the monolithic column is balanced by methanol for half an hour;
the combined system comprises the following specific operation steps:
1) firstly, the ten-way valve and the six-way valve are both in the LOAD position; the loading liquid passes through a hydroxyapatite functionalized monolithic column prepared by a pump A balance in-situ mineralization method, and the flow rate is 0.2 mL/min; the mobile phase passes through the analytical column directly by a pump B to obtain a stable baseline required by chromatographic separation, and the flow rate is 1.0 mL/min; meanwhile, filling a sample solution into a 0.5mL PEEK tube quantitative ring through a sample injection needle;
2) when the six-way valve is adjusted to the INJECT position, solid phase micro-extraction starts, a sample in a 0.5mL PEEK tube quantitative ring is brought into a hydroxyapatite functionalized monolithic column prepared by an in-situ mineralization method through a loading liquid, and the six-way valve is adjusted back to the LOAD position after a given time;
3) then, the solution conveyed by the pump A is changed from loading liquid to eluent, the flow rate is set to be 0.1mL/min, the eluent is utilized to elute an analysis object enriched on the hydroxyapatite functionalized monolithic column prepared by the in-situ mineralization method, and the analysis object is collected in a 0.2mL PEEK tube quantitative ring; when the elution is finished, the ten-way valve is adjusted to the INJECT position, the collected eluent is sent into a liquid chromatographic column by utilizing the mobile phase for separation, and then the detector is utilized for detection;
wherein, the sample solution and the loading solution consist of: methanol/water =70/30 by volume fraction ratio; the mobile phase is as follows: methanol/15 mmol/L phosphate buffer solution with pH =7.0 =30/70, wherein the 15mmol/L phosphate buffer solution with pH =7.0 contains 5mmol/L tetrabutylammonium bromide; the eluent is 15mmol/L phosphate buffer solution with pH = 7.0; the analytical column is a C18 liquid chromatographic analytical column.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910805620.5A CN110568114B (en) | 2019-08-29 | 2019-08-29 | Solid phase microextraction-high performance liquid chromatography on-line combined detection method for zoledronic acid and risedronic acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910805620.5A CN110568114B (en) | 2019-08-29 | 2019-08-29 | Solid phase microextraction-high performance liquid chromatography on-line combined detection method for zoledronic acid and risedronic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110568114A CN110568114A (en) | 2019-12-13 |
| CN110568114B true CN110568114B (en) | 2021-12-28 |
Family
ID=68776709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910805620.5A Active CN110568114B (en) | 2019-08-29 | 2019-08-29 | Solid phase microextraction-high performance liquid chromatography on-line combined detection method for zoledronic acid and risedronic acid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110568114B (en) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2928270B1 (en) * | 2008-03-10 | 2011-01-21 | Erytech Pharma | FORMULATION METHOD FOR THE PREVENTION OR TREATMENT OF BONE METASTASES AND OTHER BONE DISEASES |
| CN103182099B (en) * | 2011-12-31 | 2015-02-18 | 深圳兰度生物材料有限公司 | Porous active artificial bone and preparation method thereof |
| CN103191705B (en) * | 2013-04-15 | 2014-09-17 | 武汉大学 | Preparation method of open tubular capillary electrochromatographic column |
| US9950065B2 (en) * | 2013-09-26 | 2018-04-24 | Biontech Rna Pharmaceuticals Gmbh | Particles comprising a shell with RNA |
| CN108241026A (en) * | 2016-12-23 | 2018-07-03 | 中国科学院深圳先进技术研究院 | A kind of detection method of bisphosphonate drug |
| CN208188057U (en) * | 2018-05-22 | 2018-12-04 | 福州大学 | On-line solid phase extraction-high performance liquid chromatography combined system |
| CN108732271B (en) * | 2018-05-22 | 2023-03-31 | 福州大学 | On-line solid phase extraction detection method for adenosine triphosphate and phosphorylation metabolite thereof |
| CN108927113B (en) * | 2018-05-22 | 2021-05-18 | 福州大学 | A nano-hydroxyapatite functionalized solid phase extraction monolithic column |
-
2019
- 2019-08-29 CN CN201910805620.5A patent/CN110568114B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110568114A (en) | 2019-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kappelgaard et al. | Measurement of angiotensin II in human plasma: technical modifications and practical experience | |
| Martin et al. | The chromatographic fractionation of ribonuclease | |
| Wan et al. | Effect of route of administration and effusions on methotrexate pharmacokinetics | |
| CN102133256A (en) | Rhodiola crenulata extract and preparation method thereof | |
| Li et al. | Simultaneous speciation of selenium and mercury in human urine samples from long-term mercury-exposed populations with supplementation of selenium-enriched yeast by HPLC-ICP-MS | |
| Downes et al. | Separation of two dissolved reactive phosphorus fractions in lakewater | |
| Pérez-Corona et al. | Living organisms as an alternative to hyphenated techniques for metal speciation. Evaluation of baker's yeast immobilized on silica gel for Hg speciation | |
| Jankowski et al. | Increased vascular growth in hemodialysis patients induced by platelet-derived diadenosine polyphosphates | |
| Dabek et al. | Assay for plasma 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 by" high-performance" liquid chromatography. | |
| CN110568114B (en) | Solid phase microextraction-high performance liquid chromatography on-line combined detection method for zoledronic acid and risedronic acid | |
| Palmisano et al. | Determination of methotrexate in untreated body fluids by micellar liquid chromatography | |
| Tan et al. | Determination of thiamine (vitamin B1) in pharmaceutical tablets and human urine by titania-based ligand-exchange hydrophilic interaction chromatography | |
| Gelijkens et al. | Reversed-phase liquid chromatography of 5-fluoro-uracil nucleosides and nucleotides in the presence of quaternary ammonium ions | |
| Rößler et al. | Synthesis and chromatographic characterization of [Tc-99m] technetium-humic acid species | |
| Pérez-Ruiz et al. | A sensitive post-column photochemical derivatization/fluorimetric detection system for HPLC determination of bisphosphonates | |
| CN110575683B (en) | Hydroxyapatite functionalized monolithic column prepared by in-situ mineralization method | |
| CN112034066B (en) | Method for separating and measuring Ribociclib and impurities | |
| Mikelsons et al. | Liquid chromatography of tin-reduced technetium-hydroxyethylidenediphosphonate complexes for on-line spectral characterization and double isotope labeling | |
| El-Yazigi et al. | Liquid chromatographic analysis of mesna and dimesna in plasma and urine of patients treated with mesna | |
| CN103588826B (en) | The isolation and purification method of oligomeric tetrose in a kind of compound Salviae Miltiorrhizae extractum | |
| Boismenu et al. | Measurement of sulfate concentrations and tracer/tracee ratios in biological fluids by electrospray tandem mass spectrometry | |
| Cashaw et al. | A method for determination of subpicomole concentrations of tetrahydropapaveroline in rat brain by high-performance liquid chromatography with electrochemical detection | |
| CN108732271B (en) | On-line solid phase extraction detection method for adenosine triphosphate and phosphorylation metabolite thereof | |
| Ings et al. | Disposition, pharmacokinetics, and metabolism of 14C-fotemustine in cancer patients | |
| Coassolo et al. | Determination of midazolam and its major hydroxy metabolite in plasma by gas liquid chromatography. Application to a pharmacokinetic study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |